NasdaqGM - Delayed Quote USD

Biora Therapeutics, Inc. (BIOR)

0.2200

-0.1904

(-46.39%)

At close: December 30 at 3:55:03 PM EST

Biora Therapeutics undertakes Chapter 11 sales process

Biora Therapeutics (BIOR) has reached an agreement with certain of its prepetition creditors to provide financing to support a chapter 11 sale process, which will ultimately lead to a strengthened balance sheet and help enable it to launch its next stage of product development. To effectuate the transaction, the Company has filed a voluntary petition under chapter 11 of the U.S. Bankruptcy Code in the District of Delaware. Throughout this process, Biora expects to operate its business as usual a

TipRanks 5 days ago

BIOR
-46.39%
Biora Therapeutics Files for Chapter 11, Secures $10.25 Million Financing for Sale Process

Biora Therapeutics (BIOR) said Monday it filed a voluntary petition for Chapter 11 in the district o

PREMIUM
MT Newswires 6 days ago

BIOR
-46.39%
Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth

Sale process will help enable next stage of product development Secures up to $10.25 million in new financing to support ongoing business operations SAN DIEGO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (“Biora” or the “Company”), a biotech company developing smart pill-based therapeutic platforms, today announced it has reached an agreement with certain of its prepetition creditors (the “Lenders”) to provide financing to support a chapter 11 sale process, which will ultimately l

GlobeNewswire 6 days ago

BIOR
-46.39%
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable Company granted extension until December 9 to regain compliance with Nasdaq listing requirements for market value of securities SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended Septem

GlobeNewswire last month

BIOR
-46.39%
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2024. Company management will host a webcast and conference call on Thursday, November 14, 2024, after the close of financial markets. Conference Call and Webcast InformationDate: Thursday, November 14, 2024Time: 4:30 PM Eastern time / 1:

GlobeNewswire last month

BIOR
-46.39%
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 745,342 shares of the Company’s common stock at an offering price of $4.025 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants

GlobeNewswire 2 months ago

BIOR
-46.39%
Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting

Expanded collaborations to support rapid testing in advanced animal models in Q4 2024SAN DIEGO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today is sharing progress on its development of the BioJet™ Oral Delivery Platform, which is designed to replace injection with needle-free, oral delivery, at the 14th Annual Partnership in Drug Delivery (PODD) meeting in Boston, Massachusetts. “We have now demonstrated the

GlobeNewswire 2 months ago

BIOR
-46.39%
Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting

SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that Adi Mohanty, CEO of Biora Therapeutics, will present on the company’s 00-size BioJet™ device at the 14th Annual Partnership Opportunities in Drug Delivery (PODD) meeting, taking place in Boston, October 28–29, 2024. “As part of the development of our clinical-ready BioJet device, we were able to reduce its size from 000 to 00, while slig

GlobeNewswire 2 months ago

BIOR
-46.39%
Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium

SAN DIEGO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will present at the 19th Annual Peptide Therapeutics Symposium, taking place virtually and in person in La Jolla, California, October 22–23, 2024. Details of the presentation are as follows: Presentation Title:Empowering Peptide Self-Administration with Needle Free Smart CapsulesDate & Time:October 22, 2024, 2:30 PM –

GlobeNewswire 2 months ago

BIOR
-46.39%
Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced an upcoming poster presentation at the American College of Gastroenterology (ACG) Annual Scientific Meeting, which will be held in Philadelphia, October 25–30, 2024. Biora’s submission was awarded a Presidential Poster Award by the ACG Abstract Selection Committee. Each year less than 5% of accepted abstracts receive this distinction for hig

GlobeNewswire 3 months ago

BIOR
-46.39%
Biora Therapeutics Achieves ISO 13485 Certification

Underscoring the company’s commitment to quality and excellenceSAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it has been awarded ISO 13485:2016 certification by TÜV SÜD America, demonstrating the company’s commitment to compliance with the most rigorous global regulatory and quality standards. “We are proud of the robust systems our team has built, ensuring stringent control over develo

GlobeNewswire 3 months ago

BIOR
-46.39%
Biora Therapeutics Announces Positive Nasdaq Listing Decision

Company granted extension to regain compliance with Nasdaq listing requirementsSAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that the company has been granted an extension to regain compliance with Nasdaq listing requirements. “We shared with Nasdaq the upcoming company catalysts that we believe will drive significant value for shareholders, and we are pleased with their decision to gran

GlobeNewswire 4 months ago

BIOR
-46.39%
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will participate in the H.C. Wainwright 26th Annual Global Investment Conference, September 9–11, 2024. H.C. Wainwright 26th Annual Global Investment Conference, New York, NYCompany presentation and 1x1 investor meetingsDate:Wednesday, September 11, 2024Time:2:00 PM Eastern timeLive Webcast:https://journey.ct.events/vi

GlobeNewswire 4 months ago

BIOR
-46.39%
BIOR: Second Quarter Results

By John Vandermosten, CFA NASDAQ:BIOR READ THE FULL BIOR RESEARCH REPORT Biora Therapeutics, Inc. (NASDAQ:BIOR) reported second quarter results representing a period where the company continued refining its capital structure, announced results for its BT-600 trial, progressed with its BioJet partnership discussions and was awarded new patents. In conjunction with the 2Q:24 report, Biora announced

Zacks Small Cap Research 4 months ago

BIOR
-46.39%
Biora Therapeutics Second Quarter 2024 Earnings: EPS: US$0.18 (vs US$1.47 loss in 2Q 2023)

Biora Therapeutics ( NASDAQ:BIOR ) Second Quarter 2024 Results Key Financial Results Net income: US$6.47m (up from...

Simply Wall St. 4 months ago

BIOR
-46.39%
Q2 2024 Biora Therapeutics Inc Earnings Call

Q2 2024 Biora Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 4 months ago

BIOR
-46.39%
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan Company secures up to $16M funding from existing investors supported by BT-600 results and progress toward BioJet™ partnership Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeut

GlobeNewswire 4 months ago

BIOR
-46.39%
Biora Therapeutics Announces Funding Agreement with Existing Investors

$16 million multiple-draw facility to be used as a bridge to anticipated pharma partnershipSAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced the signing of financing agreements with its existing convertible notes holders. “We appreciate the continued commitment of our existing noteholders, who have agreed to an additional investment in Biora that we expect will fund us to important milestone

GlobeNewswire 4 months ago

BIOR
-46.39%
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update

SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the second quarter ended June 30, 2024. Company management will host a webcast and conference call on Monday, August 12, 2024, after the close of financial markets. Conference Call and Webcast InformationDate:Monday, August 12, 2024Time:4:30 PM Eastern time / 1:30 PM Pacific

GlobeNewswire 4 months ago

BIOR
-46.39%
Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference

SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will participate in the Canaccord Genuity 44th Annual Growth Conference, August 13–15, 2024. Canaccord Genuity 44th Annual Growth Conference, Boston, MACompany presentation and 1x1 investor meetings Date: Tuesday, August 13, 2024 Time: 2:30 PM Eastern time Live Webcast:https://wsw.com/webcast/canaccord98/bior/2458676 A

GlobeNewswire 4 months ago

BIOR
-46.39%

Performance Overview

Return	BIOR	S&P 500
YTD	0.00%	+0.60%
1-Year	-98.35%	+25.29%
3-Year	-99.96%	+24.68%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Biora Therapeutics, Inc. (BIOR)

Biora Therapeutics undertakes Chapter 11 sales process

Biora Therapeutics Files for Chapter 11, Secures $10.25 Million Financing for Sale Process

Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting

Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting

Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium

Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024

Biora Therapeutics Achieves ISO 13485 Certification

Biora Therapeutics Announces Positive Nasdaq Listing Decision

Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

BIOR: Second Quarter Results

Biora Therapeutics Second Quarter 2024 Earnings: EPS: US$0.18 (vs US$1.47 loss in 2Q 2023)

Q2 2024 Biora Therapeutics Inc Earnings Call

Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Biora Therapeutics Announces Funding Agreement with Existing Investors

Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference

Performance Overview